SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials.

Kidney Med · 2021 · PMC8551546 · PMID 34746739

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP = 0.12not close (p > 0.1)

In stratified analyses by eGFR, the absolute risk reduction for kidney disease progression ( Fig 1 A) appeared to be greater in lower eGFR subgroups with modest heterogeneity ( I 2 = 53.0%), but it did not reach statistical significance ( P = 0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.